Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI assistant could spot hidden liver and pancreas cancers earlier

NCT ID NCT07716670

Diagnosis Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This study is developing and testing an artificial intelligence (AI) system designed to help doctors diagnose diseases of the liver, bile ducts, and pancreas. The AI acts like a smart assistant that talks with patients to collect their symptoms, risk factors, and medical history, then creates a structured summary for the doctor. The trial involves 400 adults aged 18 to 75 who have or are suspected of having these conditions. The goal is to see whether the AI-generated summaries improve the completeness and accuracy of the information doctors have when making a diagnosis.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
an AI-based multi-agent pre-consultation system that collects symptoms and generates diagnostic summaries
What this could lead to
If successful, this AI tool could help doctors catch liver, bile duct, and pancreas diseases earlier, reducing misdiagnosis in busy clinics.
What could go wrong
This is an early-stage study focused on developing and testing the AI system, not on patient outcomes. The AI may not improve diagnosis in real-world settings and could introduce errors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 400 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population will consist of adult outpatients (aged 18-75 years) with suspected or confirmed hepatobiliary and pancreatic diseases (e.g., liver cancer, pancreatic cancer, cholangiocarcinoma, cirrhosis) who are scheduled for routine outpatient consultations at participating healthcare institutions. Participants must demonstrate sufficient cognitive function (Mini-Mental State Examination \[MMSE\] score ≥24) and proficiency in Mandarin or English to ensure effective interaction with the AI multi-agent system. All individuals must provide written informed consent and be capable of completing all study procedures, including structured interactions with the AI system and follow-up physician evaluations.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age and Gender: Patients aged 18 to 75 years, of either sex. * Clinical Diagnosis Requirements: Suspected or confirmed hepatobiliary or pancreatic diseases (e.g., liver cancer, pancreatic cancer, cholangiocarcinoma, cirrhosis) based on preliminary clinical evaluation. * Ability to provide a complete medical history and symptoms for AI system interaction. * Cognitive and Physical Capacity: * Sufficient cognitive function to complete interactions with the AI multi-agent system independently (verified by Mini-Mental State Examination \[MMSE\] score ≥24). * Proficiency in Mandarin or English to ensure accurate communication with the system. * Consent and Compliance: Willingness to participate and provide written informed consent. * Ability to complete all study procedures, including physician consultations and follow-up assessments. * Clinical Workflow Compatibility: Scheduled for outpatient consultation at participating healthcare facilities. Exclusion Criteria: * Patients with life-threatening conditions requiring immediate intervention (e.g., acute hepatic failure, severe hemorrhage). * Presence of severe cardiovascular or cerebrovascular diseases that may interfere with study participation. * Cognitive or Communication Barriers: * Cognitive impairment (MMSE score \<24) or language barriers preventing effective interaction with the AI system. * Psychiatric disorders or altered mental status affecting decision-making capacity. * Prior or Concurrent Participation: * Enrollment in other interventional clinical trials that may confound the study outcomes. * Current use of experimental diagnostic tools or AI systems outside the study protocol. * Technical or Logistical Constraints: * Inability to access or operate electronic devices required for AI system interaction (e.g., touchscreen terminals, mobile apps). * Lack of stable internet connectivity for system access. * Ethical or Legal Restrictions: Pregnancy or lactation (to avoid potential risks not directly related to the study).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Artificial intelligence (AI) in diagnosis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

biliary tract disorder Digestive System Diseases gallbladder disorder hepatobiliary disorder liver disorder pancreas disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Artificial intelligence (AI) in diagnosis Biliary disease Hepatic disease Pancreas disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.